EGFR-TKIs联合放疗治疗NSCLC的临床效果分析

Clinical Analysis of EGFR-TKIs Combined with Radiotherapy for Treatment of Patients with NSCLC

目的探讨表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKIs)联合放疗治疗非小细胞肺癌(NSCLC)患者的临床效果。方法选取2013年1月~2015年12月在我院接受治疗的110例NSCLC患者进行回顾性分析,其中60例患者仅接受吉非替尼治疗(A组)、50例患者采用吉非替尼联合放射治疗(B组),分析比较两组患者的疗效差异。结果 B组缓解率为66.66%,高于A组的46.67%,差异具有统计学意义(P<0.05);B组总有效率为94.00%,A组为90.00%,差异无统计学意义(P>0.05)。治疗结束后,B组血清CEA、CA125、CA242均显著低于A组(P<0.05)。两组患者恶心呕吐、腹泻、皮疹及白细胞减少的发生率比较,差异无统计学意义(P>0.05);B组放射性肺炎发生率为20.00%,显著高于A组的0.00%(P<0.05)。随访1年,B组生存率为56.00%,A组为43.33%,差异无统计学意义(P>0.05);两组患者的生存时间比较,差异无统计学意义(P>0.05)。结论 EGFR-TKIs联合放疗治疗NSCLC患者近期疗效优于单纯使用EGFR-TKIs,但是患者的远期受益不明显。

Objective To investigate the clinical effect of epidermal growth factor receptor tyrosine kinase inhibitor(EGFR-TKIs)combined with radiotherapy for treatment of patients with non-small cell lung cancer(NSCLC).Methods A total of110NSCLC patients treated in our hospital(January2013to December2015)were analyzed retrospectively,including60cases of patients received gefitinib treatment(group A),50patients were treated with gefitinib plus radiotherapy(group B),the curative effect difference were compared between the two groups.Results The remission rateof the patients in group B was66.66%which was higher than that in group A(46.67%),the difference was statistically significant(P<0.05);total efficiencyof patients in group B was94%and in group A was90%,the difference was not statistically significant(P>0.05);after treatment,serum CEA,CA125,CA242of patients in group B were significantly lower than that in group A(P<0.05);nausea and vomiting,diarrhea,rash and neutropenia were not statistically significant between the two groups(P>0.05);the incidence rate of radioactive pneumonia patients in group B was20%which was higher than that in group A(0%)(P<0.05);the survival rate of patients in both groups had no significant difference after follow-up for1year;there was no significant difference in the survival time of the patients between the two groups(P>0.05).Conclusion EGFR-TKIs combined with radiotherapy for treatment of patients with NSCLC has better effect than the simple use of EGFR-TKIs,but the long-term return is not obvious.